Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease

American Heart Journal

Volumn 138, Issue 5 II, 1999, Pages

  Gupta, S ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CD11B ANTIGEN; FIBRINOGEN; GLYCOPROTEIN P 15095; ROXITHROMYCIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL ACTIVATION; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFICACY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MONOCYTE; PRIORITY JOURNAL;

EID: 0032717345     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-8703(99)70296-6     Document Type: Conference Paper

References (13)

1. Gupta S, Camm AJ. Chlamydia pneumoniae and coronary heart disease: coincidence, association or causation? BMJ 1997;314:1778-9.
2. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-6.
3. Gupta S, Leatham EW, Carrington D, et al. The effect of azithromycin in post myocardial infarction patients with elevated Chlamydia pneumoniae antibody titers [abstract]. J Am Coll Cardiol 1997;755:209.
4. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
5. Rizzato G, Montemurro L, Fraioli P, et al. Efficacy of a 3-day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J 1995;8:398-402.
6. Foulds G, Shepard RM, Johnson RB. The pharmacokinetic of azithromycin in human serum and tissue. J Antimicrob Chemother 1990;25(suppl A):73-82.
7. Black PN. Anti-inflammatory effects of macrolide antibiotics. Eur Respir J 1997;10:971-2.
8. Gurfinkel E, Bozovich G, Daroca A, et al. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.
9. Gupta S, Camm AJ. Is there an infective aetiology to atherosclerosis? Drugs Aging 1998;13:1-7.
10. Bengston A, Karlsson T, Hjalmarson Å, et al. Complications prior to revascularisation among patients waiting for coronary artery bypass grafting and percutaneous transluminal coronary angioplasty. Eur Heart J 1996;17:1846-51.
11. Anderson JL, Muhlestein JB. Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia. ACADEMIC study. Presented at the 47th Scientific Session of the American College of Cardiology meeting, Atlanta, Ga, 1998.
12. Gupta S, Kaski JC, Camm AJ. Antibiotic therapy in coronary heart disease: hype versus hope. Br J Cardiol 1998;5:65-6.
13. Hart CA. Antibiotic resistance: an increasing problem? BMJ 1998;316:1255-6.